ArticleOncology research2019
miR-363-3p Inhibits Osteosarcoma Cell Proliferation and Invasion via Targeting SOX4.
Article in Oncology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Circulating microRNAs as Biomarkers of Brain Metastases in Lung Cancer: A Pilot Study.Journal of clinical medicine · 2026Article
- Inducer microRNAs in the glioma development: a concise review of mechanisms and insights into targeted therapy.Journal of the Egyptian National Cancer Institute · 2025Review
- MiR-363-3p induces tamoxifen resistance in breast cancer cells through PTEN modulation.Scientific reports · 2024Article
- Role of microRNA-363 during tumor progression and invasion.Journal of physiology and biochemistry · 2024Review
- miR-3195 suppresses the malignant progression of osteosarcoma cells via targeting SOX4.Journal of orthopaedic surgery and research · 2023Article
- MicroRNA-363-3p inhibits colorectal cancer progression by targeting interferon-induced transmembrane protein 1.World journal of gastrointestinal oncology · 2023Article
- Signal Pathways and microRNAs in Osteosarcoma Growth and the Dual Role of Mesenchymal Stem Cells in Oncogenesis.International journal of molecular sciences · 2023Review
- circEZH2Cancer science · 2023Article
- miR‑363‑3p attenuates the oxygen‑glucose deprivation/reoxygenation‑induced neuronal injuryMolecular medicine reports · 2022Article
- MiR-363-3p promotes prostate cancer tumor progression by targeting Dickkopf 3.Journal of clinical laboratory analysis · 2022Article
- MicroRNA-363-3p, negatively regulated by long non-coding RNA small nucleolar RNA host gene 5, inhibits tumor progression by targeting Aurora kinase A in colorectal cancer.Bioengineered · 2022Article
- Long non-coding RNA CCDC144NL-AS1 promotes cell proliferation by regulating the miR-363-3p/GALNT7 axis in colorectal cancer.Journal of Cancer · 2022Article
- Identification and Validation of Dilated Cardiomyopathy-Related Genes via Bioinformatics Analysis.International journal of general medicine · 2022Article
- Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.Frontiers in immunology · 2022Review
- Long Non-coding RNA FEZF1-AS1 Promotes Growth and Reduces Apoptosis Through Regulation of miR-363-3p/PAX6 Axis in Retinoblastoma.Biochemical genetics · 2021Article
- A MicroRNA Expression Signature as Prognostic Marker for Oropharyngeal Squamous Cell Carcinoma.Journal of the National Cancer Institute · 2021Article
- Deregulation of CLTC interacts with TFG, facilitating osteosarcoma via the TGF-beta and AKT/mTOR signaling pathways.Clinical and translational medicine · 2021Article
- LncRNA NORAD, sponging miR-363-3p, promotes invasion and EMT by upregulating PEAK1 and activating the ERK signaling pathway in NSCLC cells.Journal of bioenergetics and biomembranes · 2021Article
- Progress in understanding the role of lncRNA in programmed cell death.Cell death discovery · 2021Review
- MiR-363 suppresses cell migration, invasion, and epithelial-mesenchymal transition of osteosarcoma by binding to NOB1.World journal of surgical oncology · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
miR-363-3p has been shown to suppress tumor growth and metastasis in various human cancers. However, the function of miR-363-3p in osteosarcoma (OS) has not been determined. In our study, we found that the expression of miR-363-3p was significantly downregulated in OS tissues compared with adjacent normal tissues. miR-363-3p expression was associated with the poor overall survival rate of OS patients. Moreover, we found that overexpression of miR-363-3p markedly inhibited the proliferation, migration, and invasion of U2OS and MG63 cells. Moreover, we found that SOX4 was a direct target of miR-363-3p in OS cells. Overexpression of miR-363-3p significantly inhibited the expression of SOX4. Expression levels of miR-363-3p and SOX4 were negatively correlated in OS tissues. Finally, we found that restoration of SOX4 attenuated the suppressive effects of miR-363-3p on the proliferation, migration, and invasion of U2OS and MG63 cells. Therefore, our findings demonstrated that miR-363-3p served as a tumor suppressor in OS tissues by targeting SOX4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.